Breaking Finance News

Raymond James Financial, Inc. recorded Antares Pharma Inc (NASDAQ:ATRS), raising its target to $4.30 earlier today

Having a price of $2.76, Antares Pharma Inc (NASDAQ:ATRS) traded 1.47% higher on the day. With the last close up 24.45% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. ATRS has recorded a 50-day average of $2.72 and a two hundred day average of $2.22. Trade Volume was up over the average, with 1,153,406 shares of ATRS changing hands over the typical 1,081,590

Raymond James Financial, Inc. increased the stock price target of Antares Pharma Inc (NASDAQ:ATRS) to $4.30 indicating a possible upside of 0.56%.

On Wednesday March 09, 2016, Jefferies & Co released a statement on Antares Pharma Inc (NASDAQ:ATRS) dropped the target price from $5.00 to $3.00 that suggested an upside of 2.37%.

Recent Performance Chart

Antares Pharma Inc (NASDAQ:ATRS)

Antares Pharma Inc has 52 week low of $0.79 and a 52 week high of $3.10 and has a total market value of $0.

A total of 5 analysts have released a report on the stock. 3 firms rating the stock a strong buy, 1 brokerage rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $4.50.

General Company Details For Antares Pharma Inc (NASDAQ:ATRS)

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.